Full Year 2025 Integral Diagnostics Ltd Earnings Call Transcript
Key Points
- Integral Diagnostics Ltd (ASX:IDX) achieved a significant revenue growth of 33.7% to $628 million, driven by a major merger in the radiology industry.
- The company improved its operating EBITDA margin to 20.1%, up from 19.5% in the previous year.
- Diluted earnings per share increased by 32.9%, and the dividend was raised by 21.2%.
- The merger synergies exceeded expectations, with $14 million expected annually, and $7 million already realized.
- IDX is well-positioned to capitalize on industry tailwinds such as deregulation and the national lung cancer screening program, enhancing future growth prospects.
- IDX faced challenges with clinical labor shortages, particularly radiologists, which impacted cost pressures.
- The company experienced a reduction in CT reimbursement from Medicare by 2%, affecting margins.
- New Zealand's revenue growth was more muted compared to Australia, impacting overall performance.
- There were technical issues with MRI installations at Imaging Olympic Park, affecting operational capacity.
- IDX's operating leverage was limited, with operating expenses growing faster than sales, excluding synergies.
Thank you for standing by and welcome to the Integral Diagnostics FY25 results. (Operator Instructions) I would now like to hand the conference over to Dr. Ian Kadish, CEO. Please go ahead.
Thank you very much. My name is Ian Kadish. I'm the Managing Director and the Chief Executive Officer of Integral Diagnostics. I'm joined here this morning by Craig White, Craig is our Chief Financial Officer. We're pleased to be talking to you today about Integral's results in financial year 2025.
We 2025 was a transformational year for us. We undertook the biggest merger in the radiology industry and created us second largest radiology provider with 145 clinics in every state of Australia and in the greater Auckland region of New Zealand.
We grew our revenue by 33.7% to $628 million, including a contribution from capital for 6 months. On a stand-alone basis, IDX revenue grew by 6.7% year-on-year. We improved our operating EBITDA margin by 20.1%, up 0.6%
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
